Clinical Trials Enrolling for Ovarian Cancer at Memorial Sloan Kettering Cancer Center

Mario M. Leitao, Jr, MD, FACOG, FACS, program director of Gynecologic Oncology at Memorial Sloan Kettering Cancer Center, highlights some of the phase I and II clinical trials in ovarian cancer currently enrolling at his institution. He also discusses the rationale behind a new trial that is expected to open soon.

Mario M. Leitao, Jr, MD, FACOG, FACS, program director of Gynecologic Oncology at Memorial Sloan Kettering Cancer Center, highlights some of the phase I and II clinical trials in ovarian cancer currently enrolling at his institution. He also discusses the rationale behind a new trial that is expected to open soon.

Hyperthermic intraperitoneal chemotherapy (HIPEC) is currently being used for the treatment of patients with recurrent ovarian cancer. Leitao adds that Memorial Sloan Kettering Cancer Center is also running trials on the combination of nivolumab (Opdivo) plus paclitaxel (Abraxane) and carboplatin (Paraplatin) in the neoadjuvant setting.